NEW YORK (GenomeWeb) – Exiqon yesterday announced that it has exclusively licensed two sets of microRNA-based prostate cancer biomarkers from Denmark's Aarhus University Hospital.

One biomarker profile relates to urine-based, non-invasive diagnosis of prostate cancer; the other set of biomarkers comes from tissue samples and is relevant to patient stratification for improved treatment selection. Exiqon said in a statement that it will validate the biomarkers in both retrospective and prospective studies.

Financial and other terms of the deal were not disclosed.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

The United Nations is to consider a ban on field testing gene drives at a meeting being held next week, Technology Review reports.

The Associated Press reports that gene-edited food may soon be for sale.

The US Department of Health and Human Services is beginning a series of meetings on human fetal tissue research, Stat News reports.

In Cell this week: epigenetic change linked to glioblastomas, rare and low-frequency variants contributing to multiple sclerosis risk, and more.